MA42061A - Modulateurs de k-ras - Google Patents
Modulateurs de k-rasInfo
- Publication number
- MA42061A MA42061A MA042061A MA42061A MA42061A MA 42061 A MA42061 A MA 42061A MA 042061 A MA042061 A MA 042061A MA 42061 A MA42061 A MA 42061A MA 42061 A MA42061 A MA 42061A
- Authority
- MA
- Morocco
- Prior art keywords
- ras modulators
- ras
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562157915P | 2015-05-06 | 2015-05-06 | |
| US201562158356P | 2015-05-07 | 2015-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42061A true MA42061A (fr) | 2021-03-31 |
Family
ID=57218009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042061A MA42061A (fr) | 2015-05-06 | 2016-05-06 | Modulateurs de k-ras |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10857140B2 (fr) |
| EP (1) | EP3291813A4 (fr) |
| JP (1) | JP6771023B2 (fr) |
| KR (1) | KR20180017013A (fr) |
| CN (1) | CN107847495A (fr) |
| AU (1) | AU2016258192B2 (fr) |
| BR (1) | BR112017023821A2 (fr) |
| CA (1) | CA2983927A1 (fr) |
| CL (2) | CL2017002786A1 (fr) |
| EA (1) | EA201792443A1 (fr) |
| EC (1) | ECSP17073743A (fr) |
| HK (2) | HK1251485A1 (fr) |
| IL (1) | IL255417A (fr) |
| MA (1) | MA42061A (fr) |
| MX (1) | MX2017014163A (fr) |
| PH (1) | PH12017501999A1 (fr) |
| WO (1) | WO2016179558A1 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150087628A1 (en) | 2012-04-10 | 2015-03-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| MX2017014163A (es) | 2015-05-06 | 2018-08-15 | Univ California | Moduladores de k-ras. |
| WO2017201161A1 (fr) | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
| BR112019021899A2 (pt) | 2017-04-20 | 2020-08-18 | The Regents Of The University Of California | moduladores de k-ras |
| EP3710439B1 (fr) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2019204505A2 (fr) * | 2018-04-18 | 2019-10-24 | Theras, Inc. | Modulateurs de k-ras avec une fraction de sulfonamide de vinyle |
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| EP3849536A4 (fr) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Polythérapies |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| EP3946629A4 (fr) * | 2019-03-26 | 2023-04-05 | University Of Massachusetts | Cibles thérapeutiques pour des cancers dépendant de kras oncogènes |
| EP4021444A4 (fr) | 2019-08-29 | 2023-01-04 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12d |
| US11890285B2 (en) | 2019-09-24 | 2024-02-06 | Mirati Therapeutics, Inc. | Combination therapies |
| CN110981943B (zh) * | 2019-12-02 | 2021-08-03 | 清华大学 | 多肽及其在制备药物中的用途和药物 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2023205701A1 (fr) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques et leurs utilisations |
| WO2021222278A1 (fr) * | 2020-04-27 | 2021-11-04 | Verastem, Inc. | Procédés de traitement de croissance cellulaire anormale |
| TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
| BR112022025550A2 (pt) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| EP4389751A1 (fr) | 2021-09-03 | 2024-06-26 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2024155770A2 (fr) * | 2023-01-18 | 2024-07-25 | Molecular Axiom, Llc | Compositions pour moduler l'expression de kras et leurs utilisations |
| WO2024243441A1 (fr) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| WO2025007000A1 (fr) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Composés aminés tricycliques condensés substitués et leurs utilisations en tant qu'inhibiteurs de ras |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3131527A1 (de) | 1981-08-08 | 1983-02-24 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| JPS61227567A (ja) * | 1985-04-01 | 1986-10-09 | Eisai Co Ltd | １，４−ジヒドロピリジン誘導体 |
| DK626889A (da) | 1988-12-16 | 1990-06-17 | Roussel Uclaf | Indanderivater, deres fremstilling samt laegemidler med indhold deraf |
| IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| WO1996006078A1 (fr) | 1994-08-24 | 1996-02-29 | Pfizer Pharmaceuticals Inc. | N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides utilises en tant qu'antagonistes du recepteur kappa |
| US5475109A (en) * | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| US5631251A (en) | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| ATE356114T1 (de) | 1999-06-04 | 2007-03-15 | Astrazeneca Ab | Inhibitoren von metalloproteinasen |
| EE200200065A (et) | 1999-08-12 | 2003-04-15 | Pharmacia Italia S.P.A. | 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon |
| US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| WO2003004474A1 (fr) | 2001-07-06 | 2003-01-16 | Syngenta Participations Ag | Aminoacetonitriles a action pesticide |
| WO2004033427A1 (fr) * | 2002-10-11 | 2004-04-22 | Astrazeneca Ab | Derives de piperidine 1,4 disubstituee et leur utilisation en tant qu'inhibiteurs de 11-betahsd1 |
| MXPA05009661A (es) | 2003-03-12 | 2006-03-08 | Kudos Pharm Ltd | Derivados de ftalazinona. |
| US20050119266A1 (en) | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
| GB0326029D0 (en) * | 2003-11-07 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| JPWO2005047286A1 (ja) | 2003-11-13 | 2007-05-31 | 小野薬品工業株式会社 | スピロ複素環化合物 |
| MXPA06006776A (es) | 2003-12-15 | 2007-03-23 | Almirall Prodesfarma Ag | 2,6-bisheteroaril-4-aminopirimidinas como antagonistas del receptor de adenosina. |
| WO2005073198A1 (fr) | 2004-01-16 | 2005-08-11 | Wyeth | Inhibiteurs a base de sulfonamides heterocycliques de la production des beta-amyloides contenant un azole |
| ES2399447T3 (es) * | 2006-02-17 | 2013-04-01 | F. Hoffmann-La Roche Ag | Derivados benzoil-piperidina como moduladores de 5HT2/D3 |
| CA2645652A1 (fr) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Composes de bicycloheteroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations |
| US20100267779A1 (en) | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| NZ593135A (en) | 2008-12-19 | 2013-04-26 | Novartis Ag | Isoxazoline derivatives and their use as pesticide |
| TWI574961B (zh) | 2009-05-27 | 2017-03-21 | Ｐｔｃ治療公司 | 治療癌症及非腫瘤病症之方法 |
| US8324239B2 (en) | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
| US20150087628A1 (en) * | 2012-04-10 | 2015-03-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| EP2698367A1 (fr) | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles pour le traitement du cancer |
| WO2014093230A2 (fr) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk |
| UY35464A (es) * | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| EP3401314B1 (fr) * | 2013-03-15 | 2023-11-08 | Araxes Pharma LLC | Inhibiteurs covalents de kras g12c |
| WO2015048570A2 (fr) | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Modulateurs ebi2 |
| WO2016161361A1 (fr) * | 2015-04-03 | 2016-10-06 | Nantbioscience, Inc. | Compositions et méthodes de ciblage de k-ras mutant |
| MX2017014163A (es) | 2015-05-06 | 2018-08-15 | Univ California | Moduladores de k-ras. |
| WO2017181177A1 (fr) | 2016-04-15 | 2017-10-19 | Epizyme, Inc. | Composés aryle ou hétéroaryle à substitution amine utilisés comme inhibiteurs de ehmt1 et ehmt2 |
| BR112019021899A2 (pt) | 2017-04-20 | 2020-08-18 | The Regents Of The University Of California | moduladores de k-ras |
-
2016
- 2016-05-06 MX MX2017014163A patent/MX2017014163A/es unknown
- 2016-05-06 CN CN201680037365.9A patent/CN107847495A/zh active Pending
- 2016-05-06 MA MA042061A patent/MA42061A/fr unknown
- 2016-05-06 US US15/571,475 patent/US10857140B2/en not_active Expired - Fee Related
- 2016-05-06 KR KR1020177035079A patent/KR20180017013A/ko unknown
- 2016-05-06 BR BR112017023821A patent/BR112017023821A2/pt not_active Application Discontinuation
- 2016-05-06 CA CA2983927A patent/CA2983927A1/fr not_active Abandoned
- 2016-05-06 EA EA201792443A patent/EA201792443A1/ru unknown
- 2016-05-06 EP EP16790206.3A patent/EP3291813A4/fr not_active Withdrawn
- 2016-05-06 AU AU2016258192A patent/AU2016258192B2/en not_active Ceased
- 2016-05-06 JP JP2018510695A patent/JP6771023B2/ja not_active Expired - Fee Related
- 2016-05-06 WO PCT/US2016/031344 patent/WO2016179558A1/fr active Application Filing
-
2017
- 2017-11-02 PH PH12017501999A patent/PH12017501999A1/en unknown
- 2017-11-03 IL IL255417A patent/IL255417A/en unknown
- 2017-11-03 CL CL2017002786A patent/CL2017002786A1/es unknown
- 2017-11-06 EC ECIEPI201773743A patent/ECSP17073743A/es unknown
-
2018
- 2018-08-30 HK HK18111150.3A patent/HK1251485A1/zh unknown
- 2018-09-04 HK HK18111290.4A patent/HK1251972A1/zh unknown
- 2018-11-21 CL CL2018003316A patent/CL2018003316A1/es unknown
-
2020
- 2020-10-28 US US17/082,125 patent/US11541044B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201792443A1 (ru) | 2018-10-31 |
| EP3291813A1 (fr) | 2018-03-14 |
| PH12017501999A1 (en) | 2018-04-02 |
| HK1251972A1 (zh) | 2019-05-10 |
| US10857140B2 (en) | 2020-12-08 |
| KR20180017013A (ko) | 2018-02-20 |
| ECSP17073743A (es) | 2018-03-31 |
| US20210196695A1 (en) | 2021-07-01 |
| BR112017023821A2 (pt) | 2018-07-31 |
| WO2016179558A1 (fr) | 2016-11-10 |
| AU2016258192A1 (en) | 2017-11-16 |
| CL2018003316A1 (es) | 2019-03-15 |
| JP2018519357A (ja) | 2018-07-19 |
| US11541044B2 (en) | 2023-01-03 |
| AU2016258192B2 (en) | 2021-07-29 |
| CL2017002786A1 (es) | 2018-06-22 |
| EP3291813A4 (fr) | 2019-01-02 |
| WO2016179558A8 (fr) | 2017-11-16 |
| MX2017014163A (es) | 2018-08-15 |
| HK1251485A1 (zh) | 2019-02-01 |
| US20180289683A1 (en) | 2018-10-11 |
| CA2983927A1 (fr) | 2016-11-10 |
| JP6771023B2 (ja) | 2020-10-21 |
| CN107847495A (zh) | 2018-03-27 |
| IL255417A (en) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50014A (fr) | Modulateurs de k-ras | |
| HK1251972A1 (zh) | K-ras調節劑 | |
| MA53943A (fr) | Modulateurs de ror-gamma | |
| MA55328A (fr) | Modulateurs de ror-gamma | |
| DK3283625T3 (da) | Nukleasemedieret genomeditering | |
| EP3348489A4 (fr) | Capuchon | |
| DK3297438T3 (da) | Ccr2-modulatorer | |
| DK3305788T3 (da) | Janus-kinase-hæmmer | |
| DK3331528T3 (da) | Muskarinagonister | |
| DK3277719T3 (da) | Polypeptider | |
| DK3310450T3 (da) | Olie-vand-separator | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| DK3270930T3 (da) | Præeklampsi | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
| DK3292136T3 (da) | Penicillin-g-acylaser | |
| DE112015006486A5 (de) | Inkubationsrinne | |
| DK3274482T3 (da) | Stenborsknop | |
| DK3318308T3 (da) | Badmintonketsjer | |
| DE112015005906A5 (de) | Gurtschlossbringer | |
| DE112016005599A5 (de) | Strahlungsgrill | |
| DE102015206660A8 (de) | Plattenaufteilanlage | |
| DE102015000551A8 (de) | Rotationszerstäuberturbine | |
| DE112016001124A5 (de) | Spannschutz |